| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 540 | 450 | 180 | 260 | 960 |
| Sales Growth | +20.00% | +150.00% | -30.77% | -72.92% | unch |
| Net Income | -5,020 | -4,620 | -2,600 | -1,870 | -60 |
| Net Income Growth | -8.66% | -77.69% | -39.04% | -3,016.72% | unch |
Lipella Pharmaceuticals Inc (LIPO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Lipella Pharmaceuticals Inc. is based in PITTSBURGH.
Fiscal Year End Date: 12/31